Showing 6071-6080 of 8180 results for "".
- Mohs Surgery as Effective as Wide Excision for Lentigo Maligna Melanoma: Studyhttps://practicaldermatology.com/news/mohs-surgery-effective-wide-excision-lentigo-maligna-melanoma-study/2468603/New research suggests Mohs micrographic surgery (MMS) may be as effective as wide local excision (WLE) in treating lentigo maligna (LM) and lentigo maligna melanoma (LMM), without compromising melanoma-specific survival rates. Lentigo maligna, often found on sun-damaged skin in older patie
- Botanix Announces Expanded Payer Coverage for Sofdrahttps://practicaldermatology.com/news/botanix-announces-expanded-payer-coverage-sofdra/2468602/Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis. According to a press release from Botanix, Ascent represents approximat
- Zasocitinib Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/study-zasocitinib-effective-moderate-severe-psoriasis/2468601/Results from a recent placebo-controlled trial of zasocitinib showed promise in improving skin clearance for patients with moderate to severe plaque psoriasis. The phase 2b study, conducted across multiple centers in the United States and Canada, included 259 patients treated over 12 week
- Roflumilast Cream 0.15% Receives Glamour's Best Eczema Product Award for 2024https://practicaldermatology.com/news/roflumilast-cream-015-receives-glamours-best-eczema-product-award-2024/2468585/Arcutis Biotherapeutics announced today that ZORYVE® (roflumilast) cream 0.15% has been named Best Eczema Product by Glamour magazine in its 2024 Health and Wellness Awards. The cream, which is the first once-daily FDA-approved topical treatment specifically indicated for mild to
- New AD Research Indicates 'New Standards of Care'https://practicaldermatology.com/news/new-ad-research-indicates-new-standards-care/2468544/The bar has been raised for atopic dermatitis (AD). That was the message in “Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis,” a presentation from Drs. Christopher Bunick, Brad Glick, and Alexandra Gol
- FDA Approves Emrosi for Rosaceahttps://practicaldermatology.com/news/fda-approves-emrosi-rosacea-treatment/2468543/The US Food and Drug Administration (FDA) has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) as a treatment for inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, Journey Medical (in partnership with Dr.
- Vichy Dercos Launches Advanced Scalp Line in US Markethttps://practicaldermatology.com/news/vichy-dercos-launches-advanced-scalp-solutions-us-market/2468512/Vichy Decros has announced the US launch of its new three-step system targeting scalp concerns, representing w
- New Acne Solution Prioritizes Skin Barrier Healthhttps://practicaldermatology.com/news/new-acne-solution-prioritizes-skin-barrier-health/2468513/Bioelements announced the launch of the Acne and Pore Activists Collection, a breakthrough four-piece line designed to revolutionize care for oily and acne-prone skin by prioritizing skin barrier health. “Years in the making, this innovative collection was meticulously crafted through exte
- AD Drugs Market Predicted to Grow From $10.5 Billion to $24.5 Billionhttps://practicaldermatology.com/news/ad-drugs-market-predicted-grow-105-billion-245-billion/2468511/A new market research report predicts that the global atopic dermatitis (AD) drugs market will grow at a compound annual growth rate of 9.1% from now through 2033, going from $10.5 billion in 2023 to $24.5 billion by 2033. The report, from market.us, is titled, “Atopic Dermatitis Drugs Mar
- ImmunoSkin Conference Explores Inflammatory Skin Conditionshttps://practicaldermatology.com/news/immunoskin-conference-explores-inflammatory-skin-conditions/2468494/The third annual ImmunoSkin conference was held October 26-27 in Barcelona, Spain, highlighting new therapeutic strategies and facilitating exchange about the biological mechanisms of psoriasis and atopic dermatitis through clinical case studies and expert debates. The event was hosted by